Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 86.65% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 71.32M.
Fairly Valued
The company’s latest PE is -1.40, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 127.67M shares, decreasing 7.73% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.79M shares of this stock.